Tuberculosis vaccine development; from mouse to man.
A tuberculosis (TB) vaccine candidate, Mtb72, was developed following an antigen discovery program involving a combination of expression cloning strategies and evaluation of human immune responses. Adjuvant selection was also performed, resulting in the prioritization of AS02A and AS01B, and an industrial process for vaccine production was developed. Safety, immunogenicity, and protection studies in mice, guinea pigs, rabbits, and monkeys supported the initiation of clinical development of Mtb72f in AS02A.
Reed
Steven
S
Infectious Disease Research Institute, 1124 Columbia St, Ste 600, Seattle, WA 98104, USA. sreed@idri.org
Lobet
Yves
Y
D000276:Adjuvants, Immunologic; D000818:Animals; D000942:Antigens, Bacterial / Q000276:immunology; D002986:Clinical Trials as Topic; D004353:Drug Evaluation, Preclinical; D006168:Guinea Pigs; D000882:Haplorhini; D006801:Humans; D051379:Mice; D011817:Rabbits; D014376:Tuberculosis / Q000517:prevention & control; D032581:Tuberculosis Vaccines
D000276:Adjuvants, Immunologic; D000942:Antigens, Bacterial; D032581:Tuberculosis Vaccines